Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Pulmonary Artery DenerVation Clinical Study Using the Gradient Denervation System in Heart Failure Patients With Pulmonary Hypertension Group 2 (PreVail-PH2 Study)

NCT06052072 is registered in ClinicalTrials.gov with Gradient Denervation Technologies as lead sponsor.

NCT NCT06052072
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06052072 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Pulmonary Artery DenerVation Clinical Study Using the Gradient Denervation System in Heart Failure Patients With Pulmonary Hypertension Group 2 (PreVail-PH2 Study)
Lead sponsor
Gradient Denervation Technologies
Phase
Not applicable
Overall status
Enrolling by invitation
Start date
February 20, 2024
Completion date
June 1, 2030
Enrollment
50 (estimated)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

group 2 pulmonary hypertension, heart failure